Shore Stephanie A, Cho Youngji
Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Am J Respir Cell Mol Biol. 2016 May;54(5):609-17. doi: 10.1165/rcmb.2016-0052PS.
Obesity is a risk factor for asthma, but obese subjects with asthma respond poorly to standard asthma drugs. Obesity also alters gut bacterial community structure. Obesity-related changes in gut bacteria contribute to weight gain and other obesity-related conditions, including insulin resistance and systemic inflammation. Here, we review the rationale for the hypothesis that obesity-related changes in gut bacteria may also play a role in obesity-related asthma. The metabolomes of the liver, serum, urine, and adipose tissue are altered in obesity. Gut bacteria produce a large number of metabolites, which can reach the blood and circulate to other organs, and gut bacteria-derived metabolites have been shown to contribute to disease processes outside the gastrointestinal tract, including cardiovascular disease. Here, we describe the potential roles for two such classes of metabolites in obesity-related asthma: short-chain fatty acids and bile acids. Greater understanding of the role of microbiota in obesity-related asthma could lead to novel microbiota-based treatments for these hard-to-treat patients.
肥胖是哮喘的一个风险因素,但患有哮喘的肥胖受试者对标准哮喘药物反应不佳。肥胖还会改变肠道细菌群落结构。与肥胖相关的肠道细菌变化会导致体重增加和其他与肥胖相关的病症,包括胰岛素抵抗和全身炎症。在此,我们综述了以下假说的理论依据:与肥胖相关的肠道细菌变化可能在肥胖相关哮喘中也起作用。肥胖会改变肝脏、血清、尿液和脂肪组织的代谢组。肠道细菌会产生大量代谢物,这些代谢物可进入血液并循环至其他器官,并且已证明源自肠道细菌的代谢物会促成胃肠道以外的疾病进程,包括心血管疾病。在此,我们描述了两类此类代谢物在肥胖相关哮喘中的潜在作用:短链脂肪酸和胆汁酸。更深入了解微生物群在肥胖相关哮喘中的作用可能会为这些难以治疗的患者带来基于微生物群的新型治疗方法。